CRISPR Therapeutics, ViaCyte dose type 1 diabetes patient with new cell therapy

By The Science Advisory Board staff writers

February 4, 2022 -- CRISPR Therapeutics and ViaCyte have dosed the first patient with VCTX210 in a phase I clinical trial for the treatment of type 1 diabetes (T1D).

VCTX210 is an investigational, allogeneic, gene-edited, stem cell-derived product that applies CRISPR Therapeutics' gene editing technology to ViaCyte's proprietary stem cell capabilities for the generation of pancreatic cells designed to evade recognition by the immune system. This immune-evasive cell replacement therapy is designed to enable patients to produce their own insulin.

The phase I clinical trial of VCTX210 will assess its safety, tolerability, and immune evasion in patients with T1D. This program is being advanced by CRISPR Therapeutics and ViaCyte as part of a strategic collaboration to discover, develop, and commercialize gene-edited, stem cell-derived therapies that could offer a functional cure for people living with T1D and insulin-requiring type 2 diabetes without the need for immunosuppression.

CRISPR Therapeutics is a biopharmaceutical company focused on developing gene-based medicines for serious diseases. ViaCyte is a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs.

CRISPR Therapeutics granted FDA RMAT for CTX110 for CD19+ B-cell cancers
CRISPR Therapeutics received the U.S. Food and Drug Administration (FDA) regenerative medicine advanced therapy (RMAT) designation for CTX110, an allogeneic...
ViaCyte CEO to present at Cell & Gene Meeting
ViaCyte will present data on the latest product candidates the company is developing to treat type 1 diabetes at the Alliance for Regenerative Medicine...
CRISPR Therapeutics, Nkarta partner on gene edited cancer therapies
CRISPR Therapeutics has established a strategic partnership with Nkarta to research, develop, and commercialize CRISPR/Cas9 gene edited cell therapies...
Vertex, CRISPR Therapeutics ink deal on sickle cell gene therapy
Vertex Pharmaceuticals and CRISPR Therapeutics have amended their collaboration agreement to develop, manufacture, and commercialize CTX001, an ex vivo...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter